The VEGF pathway can be inhibited by bevacizumab (BEV), a humanized monoclonal antibody binding specifically to circulating VEGF-A which received accelerated approval by the United States Food and Drug Administration (FDA) for the treatment of recurrent GBM (rGBM) in May 2009 based on results from two phase II trials (3, 4). Here, VEGFA is linked to glioblastoma.